277 related articles for article (PubMed ID: 17111783)
1. Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
Benetti G; Borzio M; Ramella G; Bellati G; Fargion S; Colombo A; Croce G; Iamoletti C; Balzola F; Rizzetto M;
Intern Emerg Med; 2006; 1(2):113-8. PubMed ID: 17111783
[TBL] [Abstract][Full Text] [Related]
2. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
3. High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.
Wartelle-Bladou C; Arpurt JP; Renou C; Pariente A; Pillon D; Nalet B; Picon M; Glibert A; Chousterman M; Grasset D; Morin T; Bernard P; Fischer D; Ramdani M; Lagier E; Rotily M;
Gastroenterol Clin Biol; 2006 Apr; 30(4):525-32. PubMed ID: 16733374
[TBL] [Abstract][Full Text] [Related]
4. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.
Pérez R; Jiménez M; Crespo J; Diago M; Enríquez J; Vaquero P; Solá R; Olcoz JL; Romero M; Salmerón J; Blanco MI; Oña M; Melón S; Rodrigo L;
J Viral Hepat; 2003 Nov; 10(6):437-45. PubMed ID: 14633177
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatitis C virus infection in patients of northern India.
Hazari S; Panda SK; Gupta SD; Batra Y; Singh R; Acharya SK
J Gastroenterol Hepatol; 2004 Sep; 19(9):1058-65. PubMed ID: 15304125
[TBL] [Abstract][Full Text] [Related]
7. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
8. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
10. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
Fattovich G; Zagni I; Fornaciari G; Minola E; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Montanari R; Paternoster C; Distasi M; Castagnetti E; Tositti G; Rizzo C; Suppressa S; Pantalena M; Lomonaco L; Scattolini C; Tagger A
J Viral Hepat; 2003 Mar; 10(2):111-7. PubMed ID: 12614467
[TBL] [Abstract][Full Text] [Related]
12. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG
Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754
[TBL] [Abstract][Full Text] [Related]
13. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
14. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
17. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
[TBL] [Abstract][Full Text] [Related]
18. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
19. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Engler S; Flechtenmacher C; Wiedemann KH; Gugler R; Stremmel W; Kallinowski B
J Viral Hepat; 2004 Jan; 11(1):60-8. PubMed ID: 14738559
[TBL] [Abstract][Full Text] [Related]
20. High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy.
Vrolijk JM; Bekkering FC; Brouwer JT; Hansen BE; Schalm SW
J Viral Hepat; 2003 May; 10(3):205-9. PubMed ID: 12753339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
